Shares of ANI Prescription drugs, Inc. (NASDAQ:ANIP – Get Free Report) have been assigned a mean ranking of “Average Purchase” from the 5 analysis corporations which might be presently protecting the agency, Marketbeat.com experiences. One funding analyst has rated the inventory with a maintain advice and 4 have issued a purchase advice on the corporate. The typical twelve-month value goal amongst brokers which have up to date their protection on the inventory within the final yr is $78.80.
A lot of analysis corporations have not too long ago commented on ANIP. HC Wainwright reiterated a “purchase” ranking and set a $94.00 goal value on shares of ANI Prescription drugs in a analysis be aware on Tuesday. StockNews.com downgraded shares of ANI Prescription drugs from a “purchase” ranking to a “maintain” ranking in a report on Saturday, September seventh. Truist Monetary reissued a “maintain” ranking and issued a $60.00 goal value (down beforehand from $80.00) on shares of ANI Prescription drugs in a analysis be aware on Wednesday, September eleventh. Lastly, Raymond James upped their value goal on shares of ANI Prescription drugs from $81.00 to $83.00 and gave the inventory an “outperform” ranking in a report on Wednesday.
View Our Newest Inventory Evaluation on ANIP
Insider Exercise
In associated information, COO Muthusamy Shanmugam offered 11,000 shares of the inventory in a transaction on Monday, July fifteenth. The shares had been offered at a mean value of $63.38, for a complete transaction of $697,180.00. Following the sale, the chief working officer now immediately owns 671,620 shares of the corporate’s inventory, valued at $42,567,275.60. The sale was disclosed in a authorized submitting with the Securities & Alternate Fee, which is accessible by way of this hyperlink. In different information, SVP Chad Gassert offered 20,000 shares of the inventory in a transaction on Monday, July 1st. The inventory was offered at a mean value of $63.44, for a complete worth of $1,268,800.00. Following the sale, the senior vp now immediately owns 193,226 shares within the firm, valued at $12,258,257.44. The sale was disclosed in a authorized submitting with the SEC, which will be accessed by way of this hyperlink. Additionally, COO Muthusamy Shanmugam offered 11,000 shares of the inventory in a transaction dated Monday, July fifteenth. The shares had been offered at a mean value of $63.38, for a complete worth of $697,180.00. Following the completion of the transaction, the chief working officer now owns 671,620 shares within the firm, valued at roughly $42,567,275.60. The disclosure for this sale will be discovered right here. Within the final quarter, insiders offered 66,007 shares of firm inventory value $4,089,790. Insiders personal 12.70% of the corporate’s inventory.
Hedge Funds Weigh In On ANI Prescription drugs
A lot of hedge funds and different institutional traders have not too long ago purchased and offered shares of the corporate. Innealta Capital LLC acquired a brand new place in ANI Prescription drugs in the course of the second quarter value roughly $65,000. Ridgewood Investments LLC purchased a brand new stake in ANI Prescription drugs within the 2nd quarter valued at about $85,000. SG Americas Securities LLC purchased a brand new place in shares of ANI Prescription drugs within the first quarter value $106,000. ADAR1 Capital Administration LLC purchased a brand new stake in ANI Prescription drugs in the course of the fourth quarter value roughly $132,000. Lastly, Clear Road Markets LLC acquired a brand new stake in ANI Prescription drugs in the course of the fourth quarter valued at roughly $140,000. 76.05% of the inventory is at the moment owned by hedge funds and different institutional traders.
ANI Prescription drugs Inventory Efficiency
Shares of ANIP inventory traded up $1.40 throughout noon buying and selling on Wednesday, hitting $61.46. 262,779 shares of the corporate had been exchanged, in comparison with its common quantity of 206,782. The agency’s 50 day transferring common value is $61.25 and its two-hundred day transferring common value is $63.80. The agency has a market capitalization of $1.29 billion, a P/E ratio of 38.41 and a beta of 0.71. ANI Prescription drugs has a 52 week low of $48.20 and a 52 week excessive of $70.81. The corporate has a debt-to-equity ratio of 0.62, a fast ratio of three.07 and a present ratio of three.97.
ANI Prescription drugs (NASDAQ:ANIP – Get Free Report) final introduced its quarterly earnings outcomes on Tuesday, August sixth. The specialty pharmaceutical firm reported $1.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.95 by $0.07. The agency had income of $138.00 million in the course of the quarter, in comparison with analysts’ expectations of $129.09 million. ANI Prescription drugs had a web margin of 5.01% and a return on fairness of 15.64%. The corporate’s income was up 18.5% on a year-over-year foundation. Throughout the identical interval within the prior yr, the corporate posted $1.06 EPS. As a gaggle, equities analysis analysts anticipate that ANI Prescription drugs will publish 3.5 earnings per share for the present yr.
About ANI Prescription drugs
ANI Prescription drugs, Inc, a biopharmaceutical firm, develops, manufactures, and markets branded and generic prescription prescribed drugs in the US and Canada. The corporate manufactures oral stable dose merchandise; semi-solids, liquids, and topicals; managed substances; and potent merchandise, in addition to performs contract improvement and manufacturing of pharmaceutical merchandise.
Featured Tales
Obtain Information & Rankings for ANI Prescription drugs Each day – Enter your electronic mail tackle under to obtain a concise every day abstract of the newest information and analysts’ scores for ANI Prescription drugs and associated firms with MarketBeat.com’s FREE every day electronic mail e-newsletter.
